CD8+ T cells also contribute to the efficacy of many cancer therapies (10), so approaches that enhance their activity within tumors through antagonism of inhibitory checkpoint receptors, such as PD-1 or CTLA-4, are showing great success in the clinic and revolutionizing outcomes for patients with otherwise incurable metastatic disease (11, 12). The gene discussed is CD8A; the disease is cancer.